Eli Lilly And Company ( (LLY) ) has released its Q4 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Eli Lilly And Company is a leading pharmaceutical company known for transforming scientific discoveries into medications that address significant health challenges such as diabetes, obesity, and cancer. In its latest earnings report, Lilly announced a 45% increase in revenue for the fourth quarter of 2024, reaching $13.53 billion, largely driven by the success of its new products like Mounjaro and Zepbound. The company achieved a notable 102% rise in earnings per share, reflecting strong financial performance. Key highlights include regulatory approvals for new drug indications, a strategic acquisition, and a significant share repurchase program. Looking forward, Lilly projects continued growth in 2025, with expected revenue between $58 billion and $61 billion, buoyed by the launch of new medicines and expansions in manufacturing capacity.